EBV specific CTL: A model for immune therapy

Vox Sanguinis

Volumn 74, Issue SUPPL. 2, 1998, Pages 497-498

  Rooney, Cliona M ^a   Heslop, H E ^a   Brenner, M K ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0031849017     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1998.tb05463.x     Document Type: Conference Paper

References (6)

1. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Ann Rev Immunol 15:405-431, 1997.
2. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunological Reviews 157;195,1997.
3. Heslop HE, Rooney CM. Adoptive Immunotherapy of EBV Lymphoproliferative Diseases. Immunological Reviews 157:217,1997.
4. Rooney CM, Smith CA, Ng C, Loftin SK, Li C, Krance RA, Brenner MK, Heslop HE. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345:9,1995.
5. Heslop HE, Ng CYC, Li C, Smith CA, Loftin SK, Krance RA, Brenner MK, Rooney CM. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes, Nature Medicine 2:551,1996.
6. Roskrow MA, Suzuki N, Gan Y, Sixbey JW, Ng CYC, Kimbrough S, Hudson MM, Brenner MK, Heslop HE, Rooney CM, EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin's disease. Blood 1998. In press.